Laura Francis Sells 25,972 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 25,972 shares of SiBone stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $20.12, for a total transaction of $522,556.64. Following the completion of the sale, the chief executive officer directly owned 291,491 shares in the company, valued at approximately $5,864,798.92. The trade was a 8.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Laura Francis also recently made the following trade(s):

• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Price Performance

Shares of NASDAQ:SIBN opened at $19.20 on Friday. The company has a quick ratio of 7.55, a current ratio of 9.15 and a debt-to-equity ratio of 0.20. The company has a market cap of $851.52 million, a P/E ratio of -56.47 and a beta of 0.66. SiBone has a 52 week low of $11.48 and a 52 week high of $21.89. The company has a 50-day moving average price of $17.81 and a 200 day moving average price of $15.42.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.06. The company had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. Research analysts predict that SiBone will post -0.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. TD Cowen raised their target price on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Weiss Ratings raised shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. UBS Group increased their price target on shares of SiBone from $24.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Truist Financial reiterated a “buy” rating and issued a $23.00 price objective (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.17.

Institutional Trading of SiBone

Large investors have recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd acquired a new position in shares of SiBone during the 4th quarter worth $29,000. Royal Bank of Canada boosted its position in shares of SiBone by 98.5% in the 4th quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares in the last quarter. Versant Capital Management Inc grew its stake in SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in SiBone by 64,700.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after acquiring an additional 1,941 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in SiBone during the 4th quarter valued at about $53,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.